Jose Daniel Restrepo Orozco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jose Daniel Restrepo Orozco has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Azahar Navarro Beltrán
2 shared publications- Clara Ruiz Torres
Hospital Arnau de Vilanova
2 shared publications - Felipe Ocampo Osorio
Centro de Investigaciones Clínicas, Unidad de Inteligencia Artificial, Fundación Valle del Lili , Cali, Valle del Cauca
2 shared publications - Francisco García-García
Computational Biomedicine Laboratory, Principe Felipe Research Center (CIPF)
2 shared publications - Jesus Alejandro Alzate-Grisales
Unidad Mixta de Imagen Biomédica e Inteligencia Artificial FISABIO-CIPF, Fundación para el Fomento de la Investigación Sanitario y Biomédica de la Comunidad Valenciana, Valencia, Spain
2 shared publications - Juan Miguel Garcia Gomez
Biomedical Data Science Laboratory (BDSLab), Instituto de Aplicaciones de las Tecnologías de la Información y de las Comunicaciones Avanzadas (ITACA), Universitat Politècnica de València (UPV), Valencia, Spain
2 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Multimodal Artificial Intelligence for Prostate Cancer Diagnosis and Risk Stratification: A Scoping Review (Preprint)
BACKGROUND Multimodal artificial intelligence (AI) may improve clinically significant prostate cancer (csPCa) detection and risk stratification by integrating imaging, histopathology, molecular, radiomic, and structured clinical data. OBJECTIVE This scoping review mapped recent evidence on multimodal AI for prostate cancer diagnosis, staging, prognosis, and treatment personalisation, with emphasis on data modalities, fusion strategies, validation, reproducibility, and clinical translation. METHODS A PRISMA-ScR-guided search of IEEE Xplore, Scopus, Web of Science, PubMed, and SpringerLink identified English-language peer-reviewed studies published from January 2021 to December 2025. Eligible studies applied AI to at least two data sources for prostate cancer detection, grading, staging, prognosis, recurrence prediction, or treatment selection. Two reviewers screened records and charted clinical task, modalities, fusion strategy, validation design, performance, and reproducibility indicators. RESULTS Twenty-six studies were included. Clinical variables were incorporated in 24 studies, multiparametric magnetic resonance imaging in 18, and whole-slide histopathology in six. Multimodal models usually outperformed unimodal baselines in paired comparisons, including PI-CAI performance above the median radiologist AUROC (0.91 vs 0.86) and trimodal PET/MRI/clinical models reporting AUC values up to 0.955. Evidence was limited by retrospective designs, small cohorts, geographic concentration, scarce public code, inconsistent calibration reporting, and no prospective workflow validation. CONCLUSIONS Multimodal AI is promising for biopsy triage, grading, staging, prognostication, and treatment selection, but current evidence supports research prioritisation rather than routine deployment. Prospective, diverse, transparent, and clinically embedded validation is required before multimodal AI can guide routine prostate cancer decisions.
- 1 July 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessMultimodal Artificial Intelligence for Prostate Cancer Diagnosis and Risk Stratification: A Scoping Review (Preprint)
BACKGROUND Multimodal artificial intelligence (AI) may improve clinically significant prostate cancer (csPCa) detection and risk stratification by integrating imaging, histopathology, molecular, radiomic, and structured clinical data. OBJECTIVE This scoping review mapped recent evidence on multimodal AI for prostate cancer diagnosis, staging, prognosis, and treatment personalisation, with emphasis on data modalities, fusion strategies, validation, reproducibility, and clinical translation. METHODS A PRISMA-ScR-guided search of IEEE Xplore, Scopus, Web of Science, PubMed, and SpringerLink identified English-language peer-reviewed studies published from January 2021 to December 2025. Eligible studies applied AI to at least two data sources for prostate cancer detection, grading, staging, prognosis, recurrence prediction, or treatment selection. Two reviewers screened records and charted clinical task, modalities, fusion strategy, validation design, performance, and reproducibility indicators. RESULTS Twenty-six studies were included. Clinical variables were incorporated in 24 studies, multiparametric magnetic resonance imaging in 18, and whole-slide histopathology in six. Multimodal models usually outperformed unimodal baselines in paired comparisons, including PI-CAI performance above the median radiologist AUROC (0.91 vs 0.86) and trimodal PET/MRI/clinical models reporting AUC values up to 0.955. Evidence was limited by retrospective designs, small cohorts, geographic concentration, scarce public code, inconsistent calibration reporting, and no prospective workflow validation. CONCLUSIONS Multimodal AI is promising for biopsy triage, grading, staging, prognostication, and treatment selection, but current evidence supports research prioritisation rather than routine deployment. Prospective, diverse, transparent, and clinically embedded validation is required before multimodal AI can guide routine prostate cancer decisions.
- Open Access
- 2 June 2026
- Published by Springer Nature in Research Square
From Data Fusion to Decision Support in Prostate Cancer: Evidence Mapping of Multimodal Artificial Intelligence for Diagnosis, Prognosis, and Treatment Selection
Artificial intelligence systems for prostate cancer are increasingly moving beyond single-source image analysis toward models that combine radiology, clinical variables, pathology, molecular measurements, and radiomics. We conducted a PRISMA-ScR-guided evidence map of peer-reviewed English-language studies published from January 2021 to December 2025 and indexed in IEEE Xplore, Scopus, Web of Science, PubMed, or SpringerLink. Eligible studies used AI or machine learning to integrate at least two information sources for prostate cancer detection, grading, staging, prognosis, recurrence prediction, or treatment selection. Two reviewers screened records and extracted study design, clinical task, input modalities, fusion approach, validation strategy, performance, reproducibility, and implementation-relevant reporting. Twenty-six studies met eligibility criteria. Clinical variables were the most frequent non-imaging input (24/26), mpMRI was the dominant imaging source (18/26), and six studies incorporated whole-slide histopathology. Reported paired comparisons usually favoured multimodal approaches, with examples including PI-CAI performance above the median radiologist AUROC (0.91 vs. 0.86) and PET/MRI/clinical models reporting AUC values up to 0.955. However, the evidence remains mostly retrospective, geographically concentrated, weakly reproducible, and rarely calibrated; none of the included studies tested a multimodal AI system prospectively inside a clinical pathway. Current findings support continued development and rigorous evaluation rather than routine deployment. The next phase of research should prioritise prospective pathway studies, diverse external validation, transparent reporting, missing-modality robustness, and patient-centred outcomes.
- 2 June 2026
- Published by Springer Nature in Research Square
Open AccessFrom Data Fusion to Decision Support in Prostate Cancer: Evidence Mapping of Multimodal Artificial Intelligence for Diagnosis, Prognosis, and Treatment Selection
Artificial intelligence systems for prostate cancer are increasingly moving beyond single-source image analysis toward models that combine radiology, clinical variables, pathology, molecular measurements, and radiomics. We conducted a PRISMA-ScR-guided evidence map of peer-reviewed English-language studies published from January 2021 to December 2025 and indexed in IEEE Xplore, Scopus, Web of Science, PubMed, or SpringerLink. Eligible studies used AI or machine learning to integrate at least two information sources for prostate cancer detection, grading, staging, prognosis, recurrence prediction, or treatment selection. Two reviewers screened records and extracted study design, clinical task, input modalities, fusion approach, validation strategy, performance, reproducibility, and implementation-relevant reporting. Twenty-six studies met eligibility criteria. Clinical variables were the most frequent non-imaging input (24/26), mpMRI was the dominant imaging source (18/26), and six studies incorporated whole-slide histopathology. Reported paired comparisons usually favoured multimodal approaches, with examples including PI-CAI performance above the median radiologist AUROC (0.91 vs. 0.86) and PET/MRI/clinical models reporting AUC values up to 0.955. However, the evidence remains mostly retrospective, geographically concentrated, weakly reproducible, and rarely calibrated; none of the included studies tested a multimodal AI system prospectively inside a clinical pathway. Current findings support continued development and rigorous evaluation rather than routine deployment. The next phase of research should prioritise prospective pathway studies, diverse external validation, transparent reporting, missing-modality robustness, and patient-centred outcomes.